The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Abstract
Comprehensive genomic profiling enables genomic biomarker detection in advanced solid tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we compare trial enrollment using ctDNA sequencing in 1,687 patients with advanced gastrointestinal (GI) cancer in SCRUM-Japan GOZILA (no. UMIN000016343), an observational ctDNA-based screening study, to enrollment using tumor tissue sequencing in the same centers and network (GI-SCREEN, 5,621 patients). ctDNA genotyping significantly shortened the screening duration (11 versus 33 days, P < 0.0001) and improved the trial enrollment rate (9.5 versus 4.1%, P < 0.0001) without compromising treatment efficacy compared to tissue genotyping. We also describe the clonal architecture of ctDNA profiles in ~2,000 patients with advanced GI cancer, which reinforces the relevance of many targetable oncogenic drivers and highlights multiple new drivers as candidates for clinical development. ctDNA genotyping has the potential to accelerate innovation in precision medicine and its delivery to individual patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This highlights the possible utility of liquid biopsies for molecular genotyping, facilitating more rapid patient access to targeted therapy options in the future (30).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [30]
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
OncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S. M., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R. D., Soumerai, T. E., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,783
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Integrated genomic characterization of oesophageal carcinoma
Sun, Q., Kelsen, D. P., Wiznerowicz, M., Lu, Y., Sandusky, G., Wan, Y., Weinhold, N., Wong, A. M., Carvalho, A. L., Luketich, J. D., et al. (2017) · Nature · doi:10.1038/nature20805 · Cited by 1,869
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Self-citationBañales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,397
Abou‐Alfa, G. K., Macarulla, T. M., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V. T., Borad, M. J., Bridgewater, J. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30157-1 · Cited by 1,159
Leighl, N. B., Page, R. D., Raymond, V. M., Daniel, D. B., Divers, S. G., Reckamp, K. L., Villalona-Calero, M. A., Dix, D., Odegaard, J. I., Lanman, R. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0624 · Cited by 593
Self-citationParikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0561-9 · Cited by 518
Research works printed but not linked: 1
- Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https://arxiv.org/abs/1303.3997 (2013). · arXiv
Cited by
Sorted by citations
Liquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Self-citationCancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Bakir, M. A., Hamilton, E. G., Diehn, M., André, F., Roy‐Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 726
Current developments in gastric cancer: from molecular profiling to treatment strategy
Alsina, M., Arrazubi, V., Díez, M., & Tabernero, J. M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00703-w · Cited by 368
Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices
Malla, M., Loree, J. M., Kasi, P. M., & Parikh, A. R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02615 · Cited by 309
Metadata
- Authors
- Nakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., Esaki, T., Komatsu, Y., Kawamoto, Y., Takahashi, N., Ueno, M., Kagawa, Y., Nishina, T., Kato, T., Yamamoto, Y., Furuse, J., Denda, T., Kawakami, H., Oki, E., Nakajima, T., Nishida, N., Yamaguchi, K., Yasui, H., Goto, M., Matsuhashi, N., Ohtsubo, K., Yamazaki, K., Tsuji, A., Okamoto, W., Tsuchihara, K., Yamanaka, T., Miki, I., Sakamoto, Y., Ichiki, H., Hata, M., Yamashita, R., Ohtsu, A., Odegaard, J. I., & Yoshino, T.
- Affiliations
- National Cancer Center Hospital East (JP)
- Aichi Cancer Center (JP)
- National Cancer Center Hospital (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Hokkaido University Hospital (JP)
- Saitama Cancer Center (JP)
- Kanagawa Cancer Center (JP)
- Kansai Rosai Hospital (JP)
- Shikoku Cancer Center (JP)
- Osaka National Hospital (JP)
- University of Tsukuba Hospital (JP)
- Kyorin University Hospital (JP)
- Chiba Cancer Center (JP)
- Kindai University Hospital (JP)
- Kyushu University (JP)
- St. Marianna University School of Medicine (JP)
- The University of Osaka (JP)
- The Cancer Institute Hospital (JP)
- Kobe Medical Center (JP)
- Osaka Medical and Pharmaceutical University Hospital (JP)
- Gifu University (JP)
- Kanazawa University (JP)
- Shizuoka Cancer Center (JP)
- Kagawa University Hospital (JP)
- Hiroshima University Hospital (JP)
- Guardant (United States) (US)
- Corresponding author
- Yoshino, Takayuki
- ORCID
- Nakamura, Yoshiaki
- Taniguchi, Hiroya
- Ikeda, Masafumi
- Bando, Hideaki
- Kato, Ken
- Morizane, Chigusa
- Esaki, Taito
- Komatsu, Yoshito
- Kawamoto, Yasuyuki
- Takahashi, Naoki
- Ueno, Makoto
- Kagawa, Yoshinori
- Nishina, Tomohiro
- Kato, Takeshi
- Yamamoto, Yoshiyuki
- Furuse, Junji
- Denda, Tadamichi
- Kawakami, Hisato
- Oki, Eiji
- Nakajima, Takako
- Nishida, Naohiro
- Yamaguchi, Kensei
- Yasui, Hisateru
- Goto, Masahiro
- Matsuhashi, Nobuhisa
- Ohtsubo, Koushiro
- Yamazaki, Kentaro
- Tsuji, Akihito
- Okamoto, Wataru
- Tsuchihara, Katsuya
- Yamanaka, Takeharu
- Sakamoto, Yasutoshi
- Ichiki, Hiroko
- Yamashita, Riu
- Ohtsu, Atsushi
- Odegaard, Justin I.
- Yoshino, Takayuki
- Venue
- Nature Medicine
- Published
- 2020-10-05
- Volume
- 26
- Issue
- 12
- Pages
- 1859-1864
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3089353724
- Cited by
- 373
- References
- 32
- Citations by year
- 2026: 41 · 2025: 57 · 2024: 60 · 2023: 71 · 2022: 73 · 2021: 67 · 2020: 3
- FWCI
- 18.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- circulating tumor DNA, liquid biopsy, advanced gastrointestinal cancer, clinical trial recruitment, clonal architecture, oncogenic drivers, precision medicine
- MeSH terms
- Circulating Tumor DNA, Adult, DNA, Neoplasm, Gastrointestinal Neoplasms, Genotype, Humans, Japan, Male, Middle Aged, Mutation, Biomarkers, Tumor, Precision Medicine, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
